Search

Displaying results 1751 - 1760 of 7687 in total
  1. Drug

    Potassium acetate

    go.drugbank.com/drugs/DB14498
    Approved

    Mixtures: ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI, ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI
  2. Drug

    Methohexital

    go.drugbank.com/drugs/DB00474
    Approved

    An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.

    Synonyms: α-DL-1-methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
  3. Drug

    Epoprostenol

    go.drugbank.com/drugs/DB01240
    ApprovedInvestigational

    A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary...

  4. Drug

    Amibegron

    go.drugbank.com/drugs/DB05395
    Investigational

    Amibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.

  5. Drug

    Loxoprofen

    go.drugbank.com/drugs/DB09212
    ApprovedInvestigational

    Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation ...

  6. Drug

    Modified vaccinia ankara

    go.drugbank.com/drugs/DB15483
    ApprovedInvestigational

    Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus.

  7. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    In June 2023, the FDA approved the use of glofitamab for the treatment of patients with relapsed or refractory DLBCL not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma … [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies -

  8. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab was also granted FDA approval on October 18, 2023.[L48551] … Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.

  9. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.

    Categories: Dopamine D2 Receptor Antagonists
  10. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated.